Elective hepatic resection

Cady, Blake; Bonneval, M; Fender, H. Roberts

doi:10.1016/0002-9610(79)90123-5

Cited by 36 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is proved by the fact that in 100 patients we resected for liver metastases, morbidity and mortality were 11% and 5%, respectively [9]. These results are in accordance with the findings of other authors [5,7,8]. Overall survival of our patients at 5 years was 28%, similar to that observed in the 2,478 patients in the Japanese study [I], but in our series, probably due to the limited number of cases, it was not possible to verify the prognostic impact of those factors that are generally considered important for survival.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Hepatic resection for hepatocellular carcinoma

et al. 1993

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

“…Consequently, immediate or long-term results may have been influenced by the characteristics of the series. Hepatomy and extended hepatectomy is usually followed by a greater morbidity and mortality [5,7], even though the experience of Iwatsuki et al…”

Section: Discussionmentioning

confidence: 99%

Hepatic resection for hepatocellular carcinoma

et al. 1993

View full text Add to dashboard Cite

“…"~"3-'4-'x,2~5 The inclusion of wedge resection of the liver with major hepatic resections in other series makes comparisons with the present report difficult. ' 9 ' 9 2 ' 3 Overall, it is clear that liver resection has become an increasingly safer procedure. More and more patients are being given the opportunity for cure or worthwhile palliation by this method.2.2U,2:!…”

Section: Other Seriesmentioning

confidence: 99%

The seventies evolution in liver surgery for cancer

Fortner

Maclean

Kim

et al. 1981

Cancer

108

View full text Add to dashboard Cite

During the past decade, one of the major changes in the field of oncology has been in the surgical approach to primary and secondary cancer of the liver. As a result of data and experience gained in liver transplantation programs and with the application of vascular surgical principles, resectability rates have been increased. The present rate of 32% has been achieved with an overall 30-day operative mortality rate of 9%. More sophisticated intraoperative and postoperative supports have been essential in achieving these results. The median operating time is now 4 3/4 hours in length. Complications are minimal. The median postoperative hospital stay is now 13 days. During the past decade, 436 patients with liver tumors were treated by the authors. It has become apparent in this experience and in that reported by others that an increasing number of patients with primary liver cancer or metastatic cancer in the liver can be cured by surgery with minimal operative risk. Adjuvant chemotherapy may increase the salvage rate. Current therapeutic results are best evaluated after staging of the liver disease: Stage I (no involvement of margins of resection, hepatic vascular structures or bile ducts; all gross disease removed): 85% three-year survival estimate, using the Kaplan-Meier method, for individuals with primary liver cancer; 71% for those with metastatic colorectal cancer. Stages II and III (regional or extrahepatic spread): 22% three-year survival for individuals with primary liver cancer but no survivors at two years with metastatic colorectal cancer. These data permit better selection of patients who are most likely to benefit from surgery.

show abstract

“…The liver is known for its regenerative capacity [ 29 ]. Abundant expression of the DNA replication marker PCNA in DIDO3-deficient livers suggests that active cell proliferation, a sign of a regenerative response, is already underway at the peak of the mutation-driven hepatitis.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis, testicular degeneration, and ataxia in DIDO3-deficient mice with altered mRNA processing

2022

View full text Add to dashboard Cite

Background mRNA processing is an essential step of gene expression; its malfunction can lead to different degrees of physiological disorder from subclinical disease to death. We previously identified Dido1 as a stemness marker and a gene involved in embryonic stem cell differentiation. DIDO3, the largest protein encoded by the Dido1 gene, is necessary for accurate mRNA splicing and correct transcription termination. The deletion of Dido1 exon16, which encodes the carboxy-terminal half of DIDO3, results in early embryonic lethality in mouse. Results We obtained mice bearing a Cre-LoxP conditional version of that deletion and studied the effects of inducing it ubiquitously in adult stages. DIDO3-deficient mice survive the deletion but suffer mild hepatitis, testicular degeneration, and progressive ataxia, in association with systemic alterations in mRNA splicing and transcriptional readthrough. Conclusions These results offer insight into the distinct vulnerabilities in mouse organs following impairment of the mRNA processing machinery, and could aid understanding of human health dependence on accurate mRNA metabolism.

show abstract

Elective hepatic resection

Cited by 36 publications

References 13 publications

Hepatic resection for hepatocellular carcinoma

Hepatic resection for hepatocellular carcinoma

The seventies evolution in liver surgery for cancer

Hepatitis, testicular degeneration, and ataxia in DIDO3-deficient mice with altered mRNA processing

Contact Info

Product

Resources

About